Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 366 of 6351
-
Can donated plasma shield newborns from chikungunya brain damage?
Disease control Recruiting nowThe goal of this clinical trial is to learn if administration of plasma, from a whole blood donation from an individual who has declared a Chikungunya infection for less than 6 months , to a newborn, whose mother has a peripartum chikungunya infection, will have an impact on the …
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New shot could replace daily pill for advanced breast cancer
Disease control Not yet recruitingThe purpose of this study is to evaluate the efficacy and safety of Letrozole SIE (injectable) compared to Femara® (oral tablet), both given together with ribociclib, for the first-line treatment of postmenopausal women with HR-positive, HER2-negative, inoperable locally advanced…
Phase 3 • Sponsor: Rovi Pharmaceuticals Laboratories • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug targets breast cancer brain tumors in early trial
Disease control Not yet recruitingThis is a multi-site prospective single-arm open-label phase 2 clinical trial including 20 participants with metastatic TNBC and active brain metastases to be treated with sacituzumab tirumotecan 4 mg/kg IV on Days 1, and 15 of every 28-day cycle until disease progression, unacce…
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug shows promise in destroying amyloidosis cells
Disease control Not yet recruitingThis research study is for people who have newly diagnosed with AL (light chain) amyloidosis and have not yet received any treatment for this condition. The purpose of this study is to evaluate whether elranatamab, a type of immunotherapy drug, can produce deep remissions and org…
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Tailored diet plans during pregnancy show promise in cutting preterm birth and diabetes risk
Disease control Not yet recruitingThe 'Standard of Care Plus' ('PLUS') model in the ROOT Study consists of analyzing select micronutrient and gene variants of pregnant females to construct trimester-specific and personalized nutrition and lifestyle recommendations in collaboration with in-person standard obstetri…
Sponsor: GrowBaby Life Project • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Weight-Loss drug mounjaro could keep hearts in rhythm after ablation
Disease control Not yet recruitingThis multicenter, randomized, open-label, blinded-endpoint trial evaluates whether weekly subcutaneous tirzepatide for 12 months reduces atrial fibrillation (AF) recurrence after catheter ablation in adults with obesity and heart failure with preserved ejection fraction (HFpEF). …
Phase 4 • Sponsor: Yunlong Wang • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
Disease control Not yet recruitingThe purpose of this clinical trial is to assess the safety and efficacy of ubamatamab in combination with first-line chemotherapy in patients with ovarian cancer. The main questions it aims to answer are: * What is the safety profile of ubamatamab when administered with carbopla…
Phase 1/2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Quick blood tests could save newborns from sepsis
Diagnosis Not yet recruitingNeonatal sepsis is a leading cause of illness and death in Neonatal Intensive Care Units (NICUs). Diagnosing it quickly is challenging because the early signs often overlap with other common newborn health issues. While a blood culture is the most accurate way to confirm an infec…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
AI reads brain tumor types from routine slides, no special stains needed
Knowledge-focused Not yet recruitingThis is a multi-center, retrospective, observational study to develop and internally validate an artificial intelligence (AI) foundation model for hierarchical classification of central nervous system (CNS) tumors using approximately 20,000 hematoxylin and eosin (H\&E) whole-slid…
Sponsor: Huashan Hospital • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Sound waves vs. overactive bladder: a new hope?
Symptom relief Not yet recruitingOveractive bladder is a condition characterized by a sudden and difficult-to-control need to urinate, which may occur with frequent urination, nighttime urination, and urine leakage. Some women continue to experience these symptoms despite lifestyle changes, behavioral therapy, a…
Sponsor: Al-Azhar University • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Can early autism diagnosis boost therapy outcomes?
Symptom relief Not yet recruitingOccupational Therapy Intervention in Children Diagnosed with Early and Late Autism Spectrum Disorder
Sponsor: SEDANUR GÜRLEK • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Can a targeted antibody calm severe eczema?
Disease control Not yet recruitingThis first-in-human study evaluates BYN-001, a humanized IgG1 monoclonal antibody targeting interleukin-25 (IL-25), a cytokine implicated in atopic dermatitis. Parts A and B are randomized, double-blind, placebo-controlled single and multiple ascending dose cohorts in healthy adu…
Phase 1 • Sponsor: Bionyra Pharma • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
A urine test that could foresee kidney danger in the ICU
Diagnosis Not yet recruitingThe purpose of this study is to evaluate the performance of the ProNephro AKI™ (NGAL) test for identifying critically ill adults at risk of developing moderate to severe acute kidney injury (KDIGO Stage 2/3) within 48 to 72 hours of ICU admission. The study will assess how accur…
Sponsor: BioPorto Diagnostics • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BR113 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BR113 for injection in patients with …
Phase 1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a rare mutation that blocks pain reveal new painkiller targets?
Knowledge-focused Not yet recruitingCongenital insensitivity to pain (CIP) comprises a group of rare genetic disorders caused by mutations in genes essential for pain sensing in humans. Among these, Marsili syndrome is caused by a dominant point mutation in the transcription factor ZFHX2, and it is characterized by…
Sponsor: Aalborg University • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Can a Feather-Light penile monitor replace the uncomfortable gold standard?
Diagnosis Not yet recruitingThis study aims to evaluate the diagnostic performance of a novel intelligent flexible penile monitoring system for erectile dysfunction (ED). The current gold standard, RigiScan Plus, often causes discomfort and disrupts sleep due to its mechanical rings, leading to potential "f…
Sponsor: Bin Xu • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Can a Life-Saving transplant leave hidden scars on a Child's mind?
Knowledge-focused Not yet recruitingPrimary immunodeficiencies (PIDs) are a large group of genetic diseases of the immune system with highly variable clinical presentations. Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the treatments offered to some patients with PIDs. It is a curative but pa…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can a new injection slow pulmonary arterial hypertension?
Disease control Recruiting nowPhase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)
Phase 1/2 • Sponsor: 35Pharma Inc • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a phone chatbot ease Veterans' chronic pain?
Symptom relief Recruiting nowChronic pain is a prevalent and debilitating condition among Veterans, often accompanied by depression, anxiety, sleep disturbances, and social isolation. Despite the availability of behavioral interventions many Veterans-particularly those with high in-person healthcare utilizat…
Sponsor: Companion IQ, Inc • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Can a gentle electric patch ease C-Section recovery?
Symptom relief Not yet recruitingThe aim of this randomized controlled trial is to evaluate the effectiveness of continuous 24-hour Transcutaneous Electrical Nerve Stimulation (TENS) as an adjunct to standard postoperative care for pain management following cesarean delivery. Eligible women undergoing cesarean d…
Sponsor: Holy Family Hospital, Nazareth, Israel • Aim: Symptom relief
Last updated Aug 26, 2026 00:00 UTC